HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Denies Remaining Sunscreen TEAs, Offers Primer On GRASE, Resources

This article was originally published in The Tan Sheet

Executive Summary

FDA denies sunscreen TEAS for L'Oreal and Merck & Co., citing data gaps, according to proposed orders. Proponents of launching additional ingredients say the decisions point to continued gridlock in changing FDA’s OTC sunscreen monograph.

You may also be interested in...



Valisure’s Benzene Testing Finds Problems With OTC Sunscreens, Cosmetic Sun Care Products

Independent lab's analysis found benzene levels at “up to three times the conditionally restricted FDA concentration limit of 2 ppm" in 10 Neutrogena sunscreen formulations.

L’Oréal’s Anthelios SX Will Launch Following FDA Approval Of UVA Filter

L'Oréal will introduce Anthelios SX, the first product on the U.S. market containing a sun filter for short UVA wave protection, this fall, the company announced July 24

EU Sustainable Chemicals Program Could Impact 60% Of Fragrance Ingredients – Givaudan

Certain rose, jasmine, cedarwood, freesia, lavender, apple, orange and musk fragrance ingredients could be eliminated purely on the basis of hazard if EU sustainable chemical principles are implemented as discussed across sectors and regulatory programs, according to Givaudan’s Greg Adamson, senior VP, global regulatory affairs and product safety for fragrance and beauty.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS123416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel